These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3082031)

  • 1. [Self-sufficiency with factor VIII in Norway. Use of freeze-dried cryoprecipitates instead of purified factor VIII concentrates].
    Solheim BG; Evensen SA; Stavem P; Glomstein A
    Tidsskr Nor Laegeforen; 1986 Jan; 106(1):16-8. PubMed ID: 3082031
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimation of the probability of post transfusion hepatitis in hemophilia treatment.
    Davis CE; Grizzle JE; Bryan JA
    Biometrics; 1973 Jun; 29(2):386-92. PubMed ID: 4709517
    [No Abstract]   [Full Text] [Related]  

  • 3. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
    Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
    Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-yield method of production of freeze-dried purified factor VIII by blood banks.
    Smit Sibinga CT; Welbergen H; Das PC; Griffin B
    Lancet; 1981 Aug; 2(8244):449-50. PubMed ID: 6115205
    [No Abstract]   [Full Text] [Related]  

  • 5. The recovery of factor VIII from fresh-frozen indated and outdated human plasma.
    Whitman DE; Switzer ME; McKee PA
    Thromb Haemost; 1976 Aug; 36(1):71-7. PubMed ID: 1036829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antihemophilic activity of donor blood].
    Shuruev AS
    Probl Gematol Pereliv Krovi; 1976; 21(9):45-6. PubMed ID: 1005391
    [No Abstract]   [Full Text] [Related]  

  • 7. A method for the production of AHG rich cryoprecipitates & their use in the management of bleeding episodes in haemophilia.
    Kwa SB; Chen YF
    Singapore Med J; 1968 Mar; 9(1):12-6. PubMed ID: 5659889
    [No Abstract]   [Full Text] [Related]  

  • 8. Storage of whole blood for up to 24 hours at ambient temperature before component preparation: implementation in the Netherlands.
    Pietersz RN
    Transfusion; 2011 Jan; 51 Suppl 1():3S-6S. PubMed ID: 21223289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of pool cryoglobulin factor 8 concentrate in the management of haemophilia.
    O'Brien JR
    Proc R Soc Med; 1967 Mar; 60(3):243-4. PubMed ID: 6020147
    [No Abstract]   [Full Text] [Related]  

  • 10. [The preparation and use of cryoprecipitates].
    Roewer J; Wilms K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1969; 91(4):496-506. PubMed ID: 4184476
    [No Abstract]   [Full Text] [Related]  

  • 11. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.
    Pool JG; Shannon AE
    N Engl J Med; 1965 Dec; 273(27):1443-7. PubMed ID: 5852902
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor VIII-related activities in therapeutic concentrates.
    Barrowcliffe TW; Kemball-Cook G; Morris G; Holt JC; Furlong RA; Peake IR
    J Lab Clin Med; 1981 Mar; 97(3):429-38. PubMed ID: 6780643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Possibilities to elevate the factor VIII yield].
    Uteg KH; Tausendfreund K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):153-69. PubMed ID: 2439416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemofil and other factor VIII concentrates.
    Med Lett Drugs Ther; 1969 Nov; 11(23):96. PubMed ID: 5375104
    [No Abstract]   [Full Text] [Related]  

  • 16. Can the supply and demand for plasma-derived products ever be reconciled? Self-sufficiency from the viewpoint of a blood transfusion service.
    Leikola J
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S15-7. PubMed ID: 7795132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
    Allain JP
    Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
    [No Abstract]   [Full Text] [Related]  

  • 18. [Occurrence and behavior of fibrin fibrinogen degradation products in concentrates of factor VIII, cryoprecipitate and dextran precipitate during long-term preservation].
    Kätzel R; Wegner H
    Z Gesamte Inn Med; 1977 Nov; 32(22):603-11. PubMed ID: 602311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
    Toolis F; McKay G; Prowse CV
    Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.